Product Description
PTH-related protein, or ''PTHrP'', is a hormone which was discovered in 1987. As its name implies, it is closely related to another hormone discovered in the 1920's named parathyroid hormone or ''PTH''. PTH has been shown to be effective in treating osteoporosis in both animals and humans. PTHrP has been shown to be effective in treating osteoporosis in laboratory animals, and there are strong scientific reasons to think that it may be effective in humans as well. (Sourced from: https://clinicaltrials.gov/ct2/show/NCT00021827)
Mechanisms of Action: No Mechanism
Novel Mechanism: No
Modality: Large Molecule
Route of Administration: Intravenous
FDA Designation: *
Approval Status: Not Approved
Approved Countries: None
Approved Indications: None
Known Adverse Events: None
Company: University of Pittsburgh
Company Location:
Company CEO:
Additional Commercial Interests: None
Clinical Description
Countries in Clinic:
Active Clinical Trial Count:
Recent & Upcoming Milestones
Highest Development Phases
Phase 2: Osteoporosis|Intervertebral Disc Degeneration
Phase 1: Bone Diseases, Endocrine|Hypercalcemia|Paraneoplastic Endocrine Syndromes|Osteoporosis|Hyperparathyroidism
Trial ID |
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
Latest Trial Update Date |
Data Updated |
|---|---|---|---|---|---|---|---|---|
NCT01333267 |
PRO10060214 | P1 |
Withdrawn |
Hypercalcemia|Bone Diseases, Endocrine|Osteoporosis|Paraneoplastic Endocrine Syndromes|Hyperparathyroidism |
2017-07-01 |
2019-03-19 |
Treatments |
|
NCT00177411 |
IRB # 0507001 | P1 |
Withdrawn |
Osteoporosis |
2007-07-01 |
2019-03-21 |
Treatments |
|
NCT03708926 |
IRB00185784 | P2 |
Withdrawn |
Intervertebral Disc Degeneration |
2023-08-01 |
2025-02-07 |
Primary Endpoints |
|
NCT00853723 |
PRO08100148 | P2 |
Completed |
Osteoporosis |
2012-02-01 |
2025-02-07 |
Primary Endpoints|Treatments |
|
NCT00021827 |
PTHrP and Osteo (completed) | P2 |
Completed |
Osteoporosis |
None |
2019-03-21 |